Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 10:06 PM ET

Healthcare Providers and Services

Company Overview of Profarma Distribuidora de Produtos Farmacêuticos S.A.

Company Overview

Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution, wholesale, and retail of pharmaceutical and hospital products in Brazil. The company operates through Pharmaceutical Distribution, Specialties, and Retail divisions. It provides medicines, personal care, beauty, and dermatological products; and toiletries, vaccines, prostheses, and hormones in the South, Southeast, Northeast, and Center-West regions of Brazil through 12 distribution centers. The company also operates approximately 123 stores in the state of Rio de Janeiro. In addition, it provides information technology, cargo and transportation planning and control, and sales ...

Avenida das Américas, 500

bloco 12, sala 106

Rio de Janeiro, RJ 22640-100

Brazil

Founded in 1961

Key Executives for Profarma Distribuidora de Produtos Farmacêuticos S.A.

Profarma Distribuidora de Produtos Farmacêuticos S.A. does not have any Key Executives recorded.

Profarma Distribuidora de Produtos Farmacêuticos S.A. Key Developments

Profarma Seeks To Raise Funds

Profarma Distribuidora de Produtos Farmacêuticos S.A. (BOVESPA:PFRM3) plans to seek additional funds for the company in the next three years. Although it did not specify how this would take place, Profarma dismissed the possibility of new debt emissions, since its EBITDA ratio rose from 3.1 to 4.5 between the first and the second quarter of 2015.

Profarma Distribuidora de Produtos Farmacêuticos S.A. Announces Consolidated and Parent Earnings Results for the Second Quarter Ended June 30, 2015

Profarma Distribuidora de Produtos Farmacêuticos S.A. announced consolidated and parent earnings results for the second quarter ended June 30, 2015. For the quarter, on consolidated basis, the company reported gross operating revenue of BRL 964,064,000 compared to BRL 1,009,202,000 for the same period a year ago. Net operating revenue was BRL 840,368,000 compared to BRL 878,613,000 for the same period a year ago. Operating income prior to financial results was BRL 21,638,000 compared to BRL 6,241,000 for the same period a year ago. Operating income was BRL 441,000 compared to BRL 1,812,000 for the same period a year ago. Net income before minority interests was BRL 126,000 compared to BRL 2,141,000 for the same period a year ago. Net income for the quarter was BRL 126,000 compared to BRL 2,141,000 for the same period a year ago. Cash used in operating activities was BRL 104,212,000 compared to BRL 11,898,000 for the same period a year ago. Additions to fixed assets were BRL 4,518,000 compared to BRL 4,064,000 for the same period a year ago. Additions to intangible assets were BRL 497,000 compared to BRL 831,000 for the same period a year ago. EBITDA was BRL 27.2 million compared to BRL 20.4 million for the same period a year ago. Net debt was BRL 331.9 million compared to BRL 167.1 million at the same period a year ago. Adjusted net income was BRL 3.2 million compared to loss of BRL 2.8 million for the same period a year ago. Adjusted EBITDA came to BRL 27.2 million, up 33.8% from second quarter of 2014, when it amounted to BRL 20.4 million. For the quarter, on parent company basis, the company reported gross operating revenue of BRL 937,486,000 compared to BRL 877,280,000 for the same period a year ago. Net operating revenue was BRL 815,957,000 compared to BRL 760,765,000 for the same period a year ago. Operating income prior to financial results was BRL 17,187,000 compared to BRL 1,122,000 for the same period a year ago. Operating income was BRL 567,000 compared to BRL 2,573,000 for the same period a year ago. Net income before minority interests was BRL 126,000 compared to BRL 2,141,000 for the same period a year ago. Net income for the quarter was BRL 126,000 compared to BRL 2,141,000 for the same period a year ago. Cash used in operating activities was BRL 93,450,000 compared to BRL 12,253,000 for the same period a year ago. Additions to fixed assets were BRL 2,951,000 compared to BRL 1,116,000 for the same period a year ago. Additions to intangible assets were BRL 431,000 compared BRL 136,000 same period a year ago.

Profarma Distribuidora de Produtos Farmacêuticos S.A. Announces Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

Profarma Distribuidora de Produtos Farmacêuticos S.A. announced consolidated and parent earnings results for the first quarter ended March 31, 2015. For the quarter, the consolidated company reported net revenues of BRL 823.707 million compared with BRL 842.608 million for the same period a year ago. EBIT was BRL 9.4 million compared with BRL 8.6 million for the same period a year ago. EBITDA was BRL 13.5 million compared with BRL 11.9 million for the same period a year ago. Net loss was BRL 7.6 million or BRL 0.2 per batch of 1,000 shares compared with BRL 13.5 million or BRL 0.4 per batch of 1,000 shares for the same period a year ago. Net debt was BRL 205.1 million compared with BRL 412.0 million for the same period a year ago. Net cash from operating activities was BRL 32.9 million compared with BRL 81.0 million for the same period a year ago. Additions to fixed assets was BRL 8.642 million compared with BRL 3.899 million for the same period a year ago. Additions to intangible assets were BRL 0.208 million compared with BRL 0.40 million a year ago. Quarter-over-quarter, gross revenue dropped by 5.7%, mainly due to a 5.7% drop in the Pharmaceutical Distribution division's sales. Adjusted EBITDA came to BRL 13.5 million in first quarter of 2015 (1.6% margin), up 13.2% from first quarter of 2014, when it amounted to BRL 11.9 million (1.4% margin) despite the split-up of the Specialties division­which added BRL 2.1 million to EBITDA in first quarter of 2014 in comparison to a negative BRL 0.1 million booked under equity income (losses) in first quarter of 2015. For the quarter, the parent company reported net operating revenues of BRL 788.945 million compared with BRL 735.492 million for the same period a year ago. Operating loss was BRL 9.811 million compared with BRL 14.763 million for the same period a year ago. Net loss was BRL 7.636 million or BRL 1848 per batch of 1,000 shares compared with BRL 13.536 million or BRL 408 per batch of 1,000 shares for the same period a year ago. Net cash from operating activities was BRL 37.654 million compared with BRL 100.489 million for the same period a year ago. Additions to fixed assets were BRL 5.656 million compared with BRL 1.320 million for the same period a year ago. EBITDA amounted to BRL 15.4 million (2.0% margin) in first quarter of 2015, rising by 19.4% and 20.8% year-over-year and quarter-over-quarter respectively. This increase mainly resulted from a 6.6% increase in sales in comparison to first quarter of 2014 and a fall in operating (SGA) expenses in absolute amounts (BRL 6.7 million) quarter-over-quarter.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Profarma Distribuidora de Produtos Farmacêuticos S.A., please visit www.profarma.com.br. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.